The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …

Lung adenocarcinoma (LADC) is a cancer treatable using targeted therapies against driver
gene aberrations. EGFR mutations and ALK fusions are frequent gene aberrations in LADC …

Purpose: By unlocking antitumor immunity, antibodies targeting programmed cell death 1
(PD-1) exhibit impressive clinical results in non–small cell lung cancer, underlining the …

While cancer development and progression can be controlled by cytotoxic T cells, it is also
known that tumor-specific CD8+ T cells become functionally impaired by acquiring a group …

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …

Simple Summary Lung cancer is currently the second leading cause of cancer death
worldwide. Cytokines are small proteins that carry messages between cells and are known …

Lung cancer remains the leading cause of cancer related death worldwide. Despite broad
advances in diagnostics and therapy, the five-year overall survival for patients with …

Therapy for advanced non-small-cell lung cancer has developed significantly with new
awareness of histologic subtype as an important factor in guiding treatment and the …

The traditional classification of lung cancer into small cell lung cancer and non‐small cell
lung cancer (NSCLC) has been transformed with the increased understanding of the …

Lung cancer is the leading cause of cancer-related mortality and will affect~ 6% of the
population. It is divided into two broad categories, small cell lung cancer and non-small cell …